Page last updated: 2024-10-23

aspirin and Infant, Small for Gestational Age

aspirin has been researched along with Infant, Small for Gestational Age in 36 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Infant, Small for Gestational Age: An infant having a birth weight lower than expected for its gestational age.

Research Excerpts

ExcerptRelevanceReference
" Trial will be individually randomized with one-to-one ratio (intervention/control) Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin."9.24A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. ( Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hambidge, KM; Hemingway-Foday, JJ; Hibberd, PL; Hoffman, MK; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Liechty, EA; Lokangaka, A; McClure, EM; Miodovnik, M; Mwenechanya, M; Patel, A; Saleem, S; Silver, R; Tshefu, A; Wallace, DD, 2017)
"In this population of women with aPLA, who had previously had an early delivery for HD and/or SGA prior to 34 weeks gestation, combined LMWH and aspirin treatment started before 12 weeks gestation in a subsequent pregnancy did not show reduction of onset of recurrent HD either <34 weeks gestation or irrespective of gestational age, compared with aspirin alone."9.22Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
"Aspirin supplementation was associated with worse outcomes related to preterm birth in smokers in a high-risk but not low-risk cohort."9.20Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth. ( Abramovici, A; Biggio, J; Cantu, J; Edwards, R; Jauk, V; Tita, A; Wetta, L, 2015)
"Daily low-dose aspirin during pregnancy was associated with lower risks of serious perinatal outcomes for individuals at increased risk for preeclampsia, without evident harms."9.12Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Henderson, JT; Redmond, N; Senger, CA; Thomas, RG; Vesco, KK, 2021)
"We assessed the effects and safety of aspirin treatment during pregnancy on fetal and neonatal outcomes."8.82Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. ( Boskovic, R; Costei, AM; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2003)
"To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)."8.31The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023)
"To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy."8.12Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022)
"The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia."8.02Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Davis, EM; Donahue, KE; Doubeni, CA; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Silverstein, M; Simon, MA; Stevermer, J; Tseng, CW; Wong, JB, 2021)
" Among 932 women, 277 in the First Affiliated Hospital of Chongqing Medical University were routinely treated with aspirin (100 mg daily) from 12 to 16 weeks to 35 weeks of gestational age, while 655 in Chongqing Health Center for Women and Children were not taking aspirin during pregnancy."8.02Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching. ( Baker, P; Kilby, MD; Liu, X; Liu, Y; Qi, H; Saffery, R; Tong, C; Wang, L; Wen, L; Ye, Y, 2021)
"Aspirin has been shown to reduce prevalence of both early-onset pre-eclampsia (ePET) and fetal growth restriction (FGR)."8.02Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13 ( Emeto, T; Hyett, J; O'Brien, C; Park, F; Phung, J, 2021)
"To evaluate the effect of low-dose aspirin, which was administered at or before the 16th week of pregnancy due to maternal characteristics and history of a pre-existing medical condition, on prevention of pre-eclampsia, and on the birth of a small-for-gestational-age (SGA) neonate without pre-eclampsia in nulliparas in primary settings."7.96Effect of current guidelines on prevention of pre-eclampsia with low-dose aspirin in primary settings: A population-based case-control study. ( Kocic, Z; Premru-Srsen, T; Verdenik, I, 2020)
"Aspirin resistance may be associated with increased risk of adverse pregnancy outcomes including preeclampsia, premature delivery and delivery of SGA newborns."7.77Aspirin resistance may be associated with adverse pregnancy outcomes. ( Huras, H; Jach, R; Musiał, J; Reroń, A; Rytlewski, K; Undas, A; Wilczak, M; Wójtowicz, A, 2011)
"Outcomes included preeclampsia (mild and severe) and SGA neonates."6.53Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis. ( Bergeron, TS; Bujold, E; Carpentier, C; McCaw-Binns, A; Roberge, S; Sibai, B, 2016)
"Outcomes included preeclampsia, severe preeclampsia, and SGA."6.53Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. ( Bujold, E; McCaw-Binns, A; Roberge, S; Sibai, B, 2016)
"This is a single site sub-study of data collected in conjunction with the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) Trial, which is listed at  ClinicalTrials."5.69Birth weight and gestational age distributions in a rural Kenyan population. ( Achieng, E; Bucher, S; Ekhaguere, OA; Esamai, FO; Kemboi, M; Liechty, EA; Marete, I; Nowak, K; Nyongesa, P; Otieno, K; Rutto, F; Tenge, C, 2023)
" Trial will be individually randomized with one-to-one ratio (intervention/control) Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin."5.24A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. ( Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hambidge, KM; Hemingway-Foday, JJ; Hibberd, PL; Hoffman, MK; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Liechty, EA; Lokangaka, A; McClure, EM; Miodovnik, M; Mwenechanya, M; Patel, A; Saleem, S; Silver, R; Tshefu, A; Wallace, DD, 2017)
"In women with defective trophoblastic invasion, as reflected by abnormal UtA Doppler, low-dose aspirin started in the first trimester does not have a significant effect on UtA impedance as pregnancy progresses; however, the study was underpowered to detect potential small effects ."5.24Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study. ( Diaz, D; Figueras, F; González de Agüero, R; Gratacos, E; Meler, E; Oros, D; Ramirez, JC; Ricart, M; Scazzocchio, E, 2017)
"In this population of women with aPLA, who had previously had an early delivery for HD and/or SGA prior to 34 weeks gestation, combined LMWH and aspirin treatment started before 12 weeks gestation in a subsequent pregnancy did not show reduction of onset of recurrent HD either <34 weeks gestation or irrespective of gestational age, compared with aspirin alone."5.22Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
"Aspirin supplementation was associated with worse outcomes related to preterm birth in smokers in a high-risk but not low-risk cohort."5.20Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth. ( Abramovici, A; Biggio, J; Cantu, J; Edwards, R; Jauk, V; Tita, A; Wetta, L, 2015)
"Daily low-dose aspirin during pregnancy was associated with lower risks of serious perinatal outcomes for individuals at increased risk for preeclampsia, without evident harms."5.12Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Henderson, JT; Redmond, N; Senger, CA; Thomas, RG; Vesco, KK, 2021)
"The results did not demonstrate a significant difference amongst low risk nulliparous women in the risks of pre-eclampsia or gestational hypertensive disorders with aspirin administration."5.12Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis. ( Devani, P; Hodgetts Morton, V; Man, R; Morris, RK, 2021)
"This was a prospective observation of pregnancy outcomes among 462 women with pregestational diabetes mellitus (White classes B-F) and singleton pregnancies who were enrolled in a multicenter trial to compare low-dose aspirin with placebo for preeclampsia prevention."5.09Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Dombrowski, M; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, M; MacPherson, C; McNellis, D; Meis, P; Miodovnik, M; Paul, R; Roberts, J; Sibai, BM; Thurnau, G; VanDorsten, JP, 2000)
"Administering low-dose aspirin to pregnant women led to small-to-moderate benefits, including reductions in pre-eclampsia (16 fewer per 1000 women treated), preterm birth (16 fewer per 1000 treated), the baby being born small-for-gestational age (seven fewer per 1000 treated) and fetal or neonatal death (five fewer per 1000 treated)."5.01Antiplatelet agents for preventing pre-eclampsia and its complications. ( Askie, LM; Duley, L; Hunter, KE; Meher, S; Seidler, AL, 2019)
" There is general consensus between guidelines (at least 4 of 6 guidelines in agreement) in early pregnancy risk selection, and use of low-dose aspirin for women with major risk factors for placental insufficiency."4.98Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. ( Anderson, NH; Figueras, F; McCowan, LM, 2018)
"We assessed the effects and safety of aspirin treatment during pregnancy on fetal and neonatal outcomes."4.82Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. ( Boskovic, R; Costei, AM; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2003)
"To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)."4.31The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023)
"To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy."4.12Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022)
" Among 932 women, 277 in the First Affiliated Hospital of Chongqing Medical University were routinely treated with aspirin (100 mg daily) from 12 to 16 weeks to 35 weeks of gestational age, while 655 in Chongqing Health Center for Women and Children were not taking aspirin during pregnancy."4.02Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching. ( Baker, P; Kilby, MD; Liu, X; Liu, Y; Qi, H; Saffery, R; Tong, C; Wang, L; Wen, L; Ye, Y, 2021)
"The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia."4.02Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Davis, EM; Donahue, KE; Doubeni, CA; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Silverstein, M; Simon, MA; Stevermer, J; Tseng, CW; Wong, JB, 2021)
"Aspirin has been shown to reduce prevalence of both early-onset pre-eclampsia (ePET) and fetal growth restriction (FGR)."4.02Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13 ( Emeto, T; Hyett, J; O'Brien, C; Park, F; Phung, J, 2021)
"To evaluate the effect of low-dose aspirin, which was administered at or before the 16th week of pregnancy due to maternal characteristics and history of a pre-existing medical condition, on prevention of pre-eclampsia, and on the birth of a small-for-gestational-age (SGA) neonate without pre-eclampsia in nulliparas in primary settings."3.96Effect of current guidelines on prevention of pre-eclampsia with low-dose aspirin in primary settings: A population-based case-control study. ( Kocic, Z; Premru-Srsen, T; Verdenik, I, 2020)
" In ASPRE, women with a singleton pregnancy identified by combined screening as being at high risk for preterm PE (> 1 in 100) participated in a trial of aspirin (150 mg/day from 11-14 until 36 weeks' gestation) compared to placebo."3.88Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. ( Akolekar, R; Cicero, S; de Paco Matallana, C; Greco, E; Janga, D; Jani, JC; Molina, FS; Nicolaides, KH; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Singh, M; Syngelaki, A; Tan, MY; Wright, D, 2018)
"Aspirin resistance may be associated with increased risk of adverse pregnancy outcomes including preeclampsia, premature delivery and delivery of SGA newborns."3.77Aspirin resistance may be associated with adverse pregnancy outcomes. ( Huras, H; Jach, R; Musiał, J; Reroń, A; Rytlewski, K; Undas, A; Wilczak, M; Wójtowicz, A, 2011)
"To evaluate the pregnancy outcome in patients with abnormal uterine artery Doppler flow velocity waveforms (FVW's) at 19-21 weeks, which were subsequently normal by 24-26 weeks, and to study the effect of low-dose aspirin on these waveforms."3.72Delayed normalization of uterine artery Doppler waveforms is not a benign phenomenon. ( Fayyad, A; Harrington, K; Kurdi, W; Thakur, V, 2004)
"Aspirin was significantly associated with a higher birthweight Z-score (0."2.84Impact of aspirin on fetal growth in diabetic pregnancies according to White classification. ( Adkins, K; Allshouse, AA; Heyborne, KD; Metz, TD, 2017)
"When superimposed preeclampsia was present, it developed at an earlier gestational age among the group without GDM (35 ± 5 vs."2.82Rate of Gestational Diabetes Mellitus and Pregnancy Outcomes in Patients with Chronic Hypertension. ( Blackwell, SC; Haidar, ZA; Leon, MG; Longo, M; Mendez-Figueroa, H; Moussa, HN; Pedroza, C; Sibai, BM, 2016)
"Women with a prior pregnancy affected by FGR have a 20% to 30% risk of recurrence, but effective preventive strategies are lacking."2.72Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies. ( Blue, NR; Page, JM; Silver, RM, 2021)
"Women at an increased risk of preeclampsia should be offered antiplatelet therapy, regardless of whether they are first seen before or after 16 weeks' gestation."2.55Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. ( Askie, L; Duley, L; Hunter, K; Meher, S, 2017)
"Outcomes included preeclampsia (mild and severe) and SGA neonates."2.53Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis. ( Bergeron, TS; Bujold, E; Carpentier, C; McCaw-Binns, A; Roberge, S; Sibai, B, 2016)
"Outcomes included preeclampsia, severe preeclampsia, and SGA."2.53Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. ( Bujold, E; McCaw-Binns, A; Roberge, S; Sibai, B, 2016)
"Treatment with aspirin and LMWH is associated with improved outcomes for women with previous late fetal loss or early delivery due to placental dysfunction (Group 2)."1.36Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. ( Bewley, S; Bramham, K; Calatayud, I; Germain, S; Hunt, BJ; Khamashta, M; Nelson-Piercy, C, 2010)
"No patients with preeclampsia or other severe complications of pregnancy were observed in the normalised group."1.31Late normalisation of uterine artery velocimetry in high risk pregnancy. ( Danti, L; Frusca, T; Scalvi, L; Soregaroli, M; Valcamonico, A, 2001)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.78)18.7374
1990's2 (5.56)18.2507
2000's4 (11.11)29.6817
2010's16 (44.44)24.3611
2020's13 (36.11)2.80

Authors

AuthorsStudies
Davidson, KW1
Barry, MJ1
Mangione, CM1
Cabana, M1
Caughey, AB1
Davis, EM1
Donahue, KE1
Doubeni, CA1
Kubik, M1
Li, L1
Ogedegbe, G1
Pbert, L1
Silverstein, M1
Simon, MA1
Stevermer, J1
Tseng, CW1
Wong, JB1
Henderson, JT1
Vesco, KK1
Senger, CA1
Thomas, RG1
Redmond, N1
Ye, Y1
Wen, L1
Liu, X1
Wang, L1
Liu, Y1
Saffery, R1
Kilby, MD1
Tong, C1
Qi, H1
Baker, P1
Hastie, R1
Tong, S1
Wikström, AK1
Walker, SP1
Lindquist, A1
Cluver, CA1
Kupka, E1
Bergman, L1
Hesselman, S1
Bucher, S1
Nowak, K1
Otieno, K1
Tenge, C1
Marete, I1
Rutto, F1
Kemboi, M1
Achieng, E1
Ekhaguere, OA1
Nyongesa, P1
Esamai, FO1
Liechty, EA2
Joudi, N1
Rode, M1
Cardoso, MIMP1
Rezende, KBC1
Da Matta, FG1
Saunders, C1
Cardoso, FFO1
Costa Junior, IB1
Gama, LB1
Amim, J1
Bornia, RG1
Duley, L2
Meher, S2
Hunter, KE1
Seidler, AL1
Askie, LM1
Premru-Srsen, T1
Kocic, Z1
Verdenik, I1
Theilen, LH1
Campbell, HD1
Mumford, SL1
Purdue-Smithe, AC1
Sjaarda, LA1
Perkins, NJ1
Radoc, JG1
Silver, RM2
Schisterman, EF1
Park, F1
O'Brien, C1
Phung, J1
Emeto, T1
Hyett, J1
Blue, NR1
Page, JM1
Man, R1
Hodgetts Morton, V1
Devani, P1
Morris, RK1
Cruz-Lemini, M1
Vázquez, JC1
Ullmo, J1
Llurba, E1
Hoffman, MK1
Goudar, SS1
Kodkany, BS1
Goco, N1
Koso-Thomas, M1
Miodovnik, M2
McClure, EM1
Wallace, DD1
Hemingway-Foday, JJ1
Tshefu, A1
Lokangaka, A1
Bose, CL1
Chomba, E1
Mwenechanya, M1
Carlo, WA1
Garces, A1
Krebs, NF1
Hambidge, KM1
Saleem, S1
Goldenberg, RL1
Patel, A1
Hibberd, PL1
Esamai, F1
Silver, R1
Derman, RJ1
Adkins, K1
Allshouse, AA1
Metz, TD1
Heyborne, KD1
McCowan, LM2
Figueras, F2
Anderson, NH1
Tan, MY1
Poon, LC1
Rolnik, DL1
Syngelaki, A1
de Paco Matallana, C1
Akolekar, R1
Cicero, S1
Janga, D1
Singh, M1
Molina, FS1
Persico, N1
Jani, JC1
Plasencia, W1
Greco, E1
Papaioannou, G1
Wright, D1
Nicolaides, KH1
Abramovici, A1
Jauk, V1
Wetta, L1
Cantu, J1
Edwards, R1
Biggio, J1
Tita, A1
Moussa, HN2
Wu, ZH1
Han, Y1
Pacheco, LD1
Blackwell, SC2
Sibai, BM3
Saade, G1
Costantine, MM1
Abheiden, C1
Van Hoorn, ME2
Hague, WM2
Kostense, PJ1
van Pampus, MG2
de Vries, J1
Bergeron, TS1
Roberge, S2
Carpentier, C1
Sibai, B2
McCaw-Binns, A2
Bujold, E2
Bezemer, D1
de Vries, JI1
Leon, MG1
Longo, M1
Pedroza, C1
Haidar, ZA1
Mendez-Figueroa, H1
Scazzocchio, E1
Oros, D1
Diaz, D1
Ramirez, JC1
Ricart, M1
Meler, E1
González de Agüero, R1
Gratacos, E1
Hunter, K1
Askie, L1
Bramham, K1
Hunt, BJ1
Germain, S1
Calatayud, I1
Khamashta, M1
Bewley, S1
Nelson-Piercy, C1
Wójtowicz, A1
Undas, A1
Huras, H1
Musiał, J1
Rytlewski, K1
Reroń, A1
Wilczak, M1
Jach, R1
Kozer, E1
Costei, AM1
Boskovic, R1
Nulman, I1
Nikfar, S1
Koren, G1
Kurdi, W1
Fayyad, A1
Thakur, V1
Harrington, K1
Buist, RG1
North, RA1
Gamble, G1
Caritis, S1
Hauth, J1
Lindheimer, M1
VanDorsten, JP1
MacPherson, C1
Klebanoff, M1
Landon, M1
Paul, R1
Meis, P1
Dombrowski, M1
Thurnau, G1
Roberts, J1
McNellis, D1
Soregaroli, M1
Valcamonico, A1
Scalvi, L1
Danti, L1
Frusca, T1
Wallenburg, HC1
van Kessel, PH1
van Hof, AC1
Ubachs, JM1
van Wersch, JW1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Best Practice Alert (BPA) for Low Dose Aspirin Recommendation in High-risk Pregnancies: a Randomized Controlled Trial[NCT05802940]640 participants (Anticipated)Interventional2023-06-19Not yet recruiting
162 mg of Aspirin for Prevention of Preeclampsia[NCT05221164]Phase 4200 participants (Anticipated)Interventional2021-07-06Recruiting
Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial[NCT03871491]Phase 334,000 participants (Anticipated)Interventional2020-09-01Active, not recruiting
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]11,976 participants (Actual)Interventional2016-03-23Completed
Correlation Between Pulmonary Artery Doppler And Other Ultrasonographic Markers With Neonatal Outcome In Placenta Accreta Spectrum Patients[NCT04911322]71 participants (Actual)Observational2021-08-15Completed
Correlation Between Pulmonary Artery Doppler And Neonatal Outcome In Hypertensive Disorders Of Pregnancy[NCT05793125]72 participants (Anticipated)Observational2023-04-03Recruiting
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513]414 participants (Anticipated)Interventional2022-03-24Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm189
Placebo Arm230

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

- Birth weight <2500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm1078
Placebo Arm1153

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

- Birth weight <1500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm78
Placebo Arm101

Fetal Outcome 4 - Incidence of Fetal Loss

- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm303
Placebo Arm353

Fetal Outcome 5 - Incidence of Spontaneous Abortion

- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm134
Placebo Arm152

Fetal Outcome 6 - Incidence of All Stillbirth

- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm141
Placebo Arm166

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm42
Placebo Arm30

Incidence of Hypertensive Disorders of Pregnancy

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

InterventionParticipants (Count of Participants)
Intervention Arm352
Placebo Arm325

Incidence of Perinatal Mortality

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm264
Placebo Arm309

Incidence of Preterm Birth

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm668
Placebo Arm754

Incidence of Small for Gestational Age (SGA)

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm1506
Placebo Arm1564

Maternal Outcome 1 - Incidence of Vaginal Bleeding

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm214
Placebo Arm246

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm26
Placebo Arm25

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm54
Placebo Arm43

Maternal Outcome 4 - Incidence of Maternal Mortality

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm9
Placebo Arm12

Maternal Outcome 5 - Incidence of Late Abortion

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm23
Placebo Arm30

Maternal Outcome 6 - Change in Maternal Hemoglobin

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

InterventionParticipants (Count of Participants)
Intervention Arm290
Placebo Arm333

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm8
Placebo Arm21

Reviews

11 reviews available for aspirin and Infant, Small for Gestational Age

ArticleYear
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA, 2021, 09-28, Volume: 326, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Infant, Newborn; Infant, Small for

2021
Aspirin in pregnancy: a review of indications, timing, dosing and efficacy.
    Current opinion in obstetrics & gynecology, 2023, 04-01, Volume: 35, Issue:2

    Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Infant, Small for Gestational Ag

2023
Antiplatelet agents for preventing pre-eclampsia and its complications.
    The Cochrane database of systematic reviews, 2019, 10-30, Volume: 2019, Issue:10

    Topics: Aspirin; Female; Gestational Age; Humans; Infant, Newborn; Infant, Small for Gestational Age; Matern

2019
Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies.
    Obstetrics and gynecology clinics of North America, 2021, Volume: 48, Issue:2

    Topics: Adult; Anticoagulants; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retardation; Gestational A

2021
Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis.
    European journal of obstetrics, gynecology, and reproductive biology, 2021, Volume: 262

    Topics: Aspirin; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Pre-Eclampsia; Pregnanc

2021
Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis.
    American journal of obstetrics and gynecology, 2022, Volume: 226, Issue:2S

    Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Gestational Ag

2022
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
    American journal of obstetrics and gynecology, 2018, Volume: 218, Issue:2S

    Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F

2018
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
    American journal of obstetrics and gynecology, 2018, Volume: 218, Issue:2S

    Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F

2018
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
    American journal of obstetrics and gynecology, 2018, Volume: 218, Issue:2S

    Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F

2018
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
    American journal of obstetrics and gynecology, 2018, Volume: 218, Issue:2S

    Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F

2018
Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis.
    American journal of perinatology, 2016, Volume: 33, Issue:6

    Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newborn; Infant, Small f

2016
Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials.
    American journal of perinatology, 2016, Volume: 33, Issue:8

    Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newborn; Infant, Small f

2016
Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis.
    American journal of obstetrics and gynecology, 2017, Volume: 216, Issue:2

    Topics: Aspirin; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Perinatal Death; Platel

2017
Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2003, Volume: 68, Issue:1

    Topics: Abnormalities, Drug-Induced; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight;

2003

Trials

10 trials available for aspirin and Infant, Small for Gestational Age

ArticleYear
Birth weight and gestational age distributions in a rural Kenyan population.
    BMC pediatrics, 2023, 03-08, Volume: 23, Issue:1

    Topics: Age Distribution; Aspirin; Birth Weight; Female; Gestational Age; Humans; Infant; Infant, Newborn; I

2023
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
    BMC pregnancy and childbirth, 2017, May-03, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl

2017
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
    BMC pregnancy and childbirth, 2017, May-03, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl

2017
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
    BMC pregnancy and childbirth, 2017, May-03, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl

2017
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
    BMC pregnancy and childbirth, 2017, May-03, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl

2017
Impact of aspirin on fetal growth in diabetic pregnancies according to White classification.
    American journal of obstetrics and gynecology, 2017, Volume: 217, Issue:4

    Topics: Adult; Aspirin; Birth Weight; Female; Fetal Development; Fetal Macrosomia; Humans; Infant, Newborn;

2017
Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth.
    American journal of perinatology, 2015, Volume: 32, Issue:5

    Topics: Adolescent; Adult; Aspirin; Cohort Studies; Double-Blind Method; Female; Humans; Infant, Newborn; In

2015
Customized versus Population Fetal Growth Norms and Adverse Outcomes Associated with Small for Gestational Age Infants in a High-Risk Cohort.
    American journal of perinatology, 2015, Volume: 32, Issue:7

    Topics: Aspirin; Birth Weight; Cesarean Section; Cyclooxygenase Inhibitors; Female; Fetal Development; Fetal

2015
Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results.
    BJOG : an international journal of obstetrics and gynaecology, 2016, Volume: 123, Issue:5

    Topics: Adult; Anticoagulants; Aspirin; Birth Weight; Blood Flow Velocity; Drug Therapy, Combination; Female

2016
Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT.
    European journal of obstetrics, gynecology, and reproductive biology, 2016, Volume: 197

    Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Australia; Drug Therapy, Co

2016
Rate of Gestational Diabetes Mellitus and Pregnancy Outcomes in Patients with Chronic Hypertension.
    American journal of perinatology, 2016, Volume: 33, Issue:8

    Topics: Adult; Aspirin; Diabetes, Gestational; Female; Gestational Age; Humans; Hypertension; Infant, Newbor

2016
Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study.
    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2017, Volume: 49, Issue:4

    Topics: Adult; Aspirin; Cell Movement; Female; Humans; Infant, Small for Gestational Age; Pre-Eclampsia; Pre

2017
Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
    American journal of obstetrics and gynecology, 2000, Volume: 182, Issue:2

    Topics: Aspirin; Birth Weight; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female;

2000

Other Studies

15 other studies available for aspirin and Infant, Small for Gestational Age

ArticleYear
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.
    JAMA, 2021, 09-28, Volume: 326, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Infant, Newborn; Infant, Small for

2021
Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching.
    BMC pregnancy and childbirth, 2021, Nov-22, Volume: 21, Issue:1

    Topics: Adult; Aspirin; China; Cohort Studies; Female; Humans; Infant, Small for Gestational Age; Pre-Eclamp

2021
Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy.
    Obstetrics and gynecology, 2022, 04-01, Volume: 139, Issue:4

    Topics: Aspirin; Birth Weight; Cohort Studies; Female; Fetal Growth Retardation; Gestational Age; Humans; In

2022
The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin.
    Pregnancy hypertension, 2023, Volume: 33

    Topics: Aspirin; Brazil; Female; Fetal Death; Fetal Growth Retardation; Gestational Age; Humans; Infant, New

2023
Effect of current guidelines on prevention of pre-eclampsia with low-dose aspirin in primary settings: A population-based case-control study.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2020, Volume: 149, Issue:3

    Topics: Adult; Aspirin; Case-Control Studies; Female; Guideline Adherence; Humans; Infant, Newborn; Infant,

2020
Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial.
    American journal of obstetrics and gynecology, 2020, Volume: 223, Issue:5

    Topics: Abruptio Placentae; Adult; Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnanc

2020
Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13
    The Australian & New Zealand journal of obstetrics & gynaecology, 2021, Volume: 61, Issue:3

    Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newborn; Infant, Small f

2021
Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE.
    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2018, Volume: 52, Issue:1

    Topics: Adult; Aspirin; Biomarkers; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newbo

2018
Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome.
    Lupus, 2010, Volume: 19, Issue:1

    Topics: Adult; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Infant, Ne

2010
Aspirin resistance may be associated with adverse pregnancy outcomes.
    Neuro endocrinology letters, 2011, Volume: 32, Issue:3

    Topics: Adult; Aspirin; Cesarean Section; Drug Resistance; Female; Fetal Distress; Humans; Infant, Newborn;

2011
Delayed normalization of uterine artery Doppler waveforms is not a benign phenomenon.
    European journal of obstetrics, gynecology, and reproductive biology, 2004, Nov-10, Volume: 117, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arteries; Aspirin; Case-Control Studies; Delayed-Act

2004
Perinatal morbidity in chronic hypertension.
    British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:2

    Topics: Adult; Aspirin; Chronic Disease; Cohort Studies; Female; Fetal Death; Humans; Hypertension; Infant M

1996
Late normalisation of uterine artery velocimetry in high risk pregnancy.
    European journal of obstetrics, gynecology, and reproductive biology, 2001, Volume: 95, Issue:1

    Topics: Arteries; Aspirin; Blood Flow Velocity; Dose-Response Relationship, Drug; Female; Fetal Death; Human

2001
Platelet life span in pregnancies resulting in small-for-gestational age infants.
    American journal of obstetrics and gynecology, 1979, Aug-01, Volume: 134, Issue:7

    Topics: Aspirin; Blood Platelets; Cell Survival; Female; Fetal Growth Retardation; Humans; Infant, Newborn;

1979
Assessment of whole-blood spontaneous platelet aggregation during pregnancy using an impedance particle counter.
    Haemostasis, 1992, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Aspirin; Electric Impedance; Female; Fetal Growth Retardation; Gestational Age; H

1992